Data from the PRECISION study of aprocitentan to be presented at the European
Society of Hypertension Annual Meeting 2024
Allschwil, Switzerland – May 31, 2024
Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of
aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented by
Prof. Krzysztof Narkiewicz, MD, PhD, at the European Society of Hypertension’s
33 r d European Meeting of Hypertension and Cardiovascular Protection, taking
place in Berlin, Germany, May 31 – June 3, 2024.
An oral presentation is scheduled for Sunday, June 2 (09:05 – 09:15 CEST) in
Convention Hall I C, as part of the “Clinical Studies” session, entitled “Blood
pressure control with aprocitentan in resistant hypertension”. The presentation
focuses on a pre-planned analysis evaluating the efficacy of aprocitentan on
the percentage of patients with controlled blood pressure according to
hypertension guidelines at different timepoints during the Phase 3 PRECISION
study. The abstract can be found here .
A poster presentation is scheduled for Saturday, June 1 (18:50 – 18:55 CEST)
as part of the session “Moderated E-poster session 7 - Clinical studies”,
entitled “Effect of high dose aprocitentan in patients with resistant
hypertension not controlled by low dose”. The presentation focuses on a
post-hoc exploratory analysis evaluating the observed long-term benefit of
increasing to a higher dose of aprocitentan (25 mg) in patients not achieving a
blood pressure control after 4 weeks on the lower dose (12.5 mg). The abstract
can be found here .
Notes to the editor
About aprocitentan
Aprocitentan is Idorsia’s once-daily, orally active, dual endothelin receptor
antagonist, which inhibits the binding of ET-1 to ET A and ET B receptors. In
May 2022, Idorsia announced positive top-line results of the Phase 3 PRECISION
study with aprocitentan for the treatment of patients with resistant
hypertension. Detailed results were published in The Lancet and presented as a
Late-Breaking Science presentation during the American Heart Association (AHA)
Scientific Sessions in November 2022. More details and commentary can be found
in the dedicated press release and an investor webcast featuring Prof. Markus
Schlaich, an investigator in PRECISION.
On March 19, 2024, aprocitentan was approved as TRYVIO in the US, with
availability planned for H2 2024. On April 25, 2024, Idorsia received a
positive opinion for aprocitentan (as JERAYGO™) from the Committee for
Medicinal Products for Human Use (CHMP) as a treatment of resistant
hypertension. A CHMP positive opinion is one of the final steps before
marketing authorization can be granted by the European Commission; a final
decision is expected approximately two months after publication of the CHMP
opinion.
About Prof. Krzysztof Narkiewicz, MD, PhD
Professor Krzysztof Narkiewicz is the Head of the Department of Hypertension
and Diabetology, Medical University of Gdansk, Gdansk, Poland. His research has
been focused on the role of the sympathetic nervous system and metabolic
factors in regulation of cardiovascular function in physiological and
pathological states, and on prevention and treatment of cardiometabolic
diseases including hypertension, diabetes, coronary artery disease, congestive
heart failure and obstructive sleep apnea. He has published over 700 full-text
publication; (> 39 000 citations; h-index: 69). He was the President of the
Scientific Council of the European Society of Hypertension (2009-2011). He was
a member of the Task Force for the Management of Arterial Hypertension of the
European Society of Hypertension (ESH) and of the European Society of
Cardiology (ESC) preparing the 2007, 2013 and 2018 Guidelines for the
Management of Arterial Hypertension. He also contributed to the 2023 ESH
hypertension guidelines.
Prof. Krzysztof Narkiewicz serves as a consultant to Idorsia.
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve this, we
will develop Idorsia into a leading biopharmaceutical company, with a strong
scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is
specialized in the discovery, development and commercialization of small
molecules to transform the horizon of therapeutic options. Idorsia has a
25-year heritage of drug discovery, a broad portfolio of innovative drugs in
the pipeline, an experienced team of professionals covering all disciplines
from bench to bedside, and commercial operations in Europe and North America –
the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June
2017 and has over 750 highly qualified specialists dedicated to realizing our
ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain 'forward-looking statements', relating
to the company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects', 'may',
'are expected to', 'will', 'will continue', 'should', 'would be', 'seeks',
'pending' or 'anticipates' or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions of the
company's investment and research and development programs and anticipated
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect the
current views of the company with respect to future events and are subject to
certain risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements of the company to be materially
different from any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those described herein
as anticipated, believed, estimated or expected.
Anhang Medienmitteilung PDF